Our study revealed that seven kinases, CTNNB1, CRK, EGFR, ERBB2, PIK3R1, PLCG1, and PTPN11, were highly activated in all NSCLC patients harboring sensitizing EGFR mutations. This evidence concerns the gene CRK and non-small cell lung carcinoma.